Venetoclax, a Bcl2 inhibitor, is commonly used in the treatment of chronic lymphocytic leukemia as a monotherapy, and in combination with other therapies for acute myeloid leukemia. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.